Document is current
Any future updates will be listed below
-
Authors
Corona, Magdalena https://orcid.org/0000-0002-6553-0171
Brown, Samantha https://orcid.org/0000-0001-5352-974X
Rejeski, Kai https://orcid.org/0000-0003-3905-0251
Flynn, Jessica R.
Devlin, Sean M. https://orcid.org/0000-0002-6801-720X
Raj, Sandeep
Luna de Abia, Alejandro
Lin, Richard J. https://orcid.org/0000-0002-0834-7880
Scordo, Michael
Shah, Gunjan L. https://orcid.org/0000-0002-9977-0456
Palomba, M. Lia
Boardman, Alexander P.
Falchi, Lorenzo
Lue, Jennifer
Salles, Gilles https://orcid.org/0000-0002-9541-8666
Park, Jae
Giralt, Sergio A. https://orcid.org/0000-0003-1944-5053
Perales, Miguel-Angel https://orcid.org/0000-0002-5910-4571
Shouval, Roni https://orcid.org/0000-0001-9827-8032
Dahi, Parastoo B. https://orcid.org/0000-0002-0794-3226
-
Funding
Funding for this research was provided by:
Dr. Magdalena Corona’s work was supported by a grant from the Alfonso Martin Escudero Foundation
Dr. Alejandro Luna’s work was supported by an FEHH/Gilead grant
Comedy vs. Cancer, Long Island Sound, Chapter, Swim Across America
- License Information
-
More Information
Article History
Received: 21 June 2025
Revised: 6 October 2025
Accepted: 7 November 2025
First Online: 18 November 2025
Competing interests
: P.B.D. has financial interest in Atara Biotherapeutics and has served on Advisory Board for Pierre Fabre Pharmaceuticals. Dr. Perales reports honoraria from Adicet, Allogene, Caribou Biosciences, Celgene, Bristol-Myers Squibb, Equilium, Exevir, ImmPACT Bio, Incyte, Kite/Gilead, Merck, Miltenyi Biotec, MorphoSys, Nektar Therapeutics, Novartis, Omeros, OrcaBio, Pierre Fabre, Sanofi, Syncopation, Takeda, VectivBio AG, and Vor Biopharma. He serves on DSMBs for Cidara Therapeutics and Sellas Life Sciences. He has ownership interests in Omeros and OrcaBio. He has received institutional research support for clinical trials from Allogene, Genmab, Incyte, Kite/Gilead, Miltenyi Biotec, Nektar Therapeutics, and Novartis. R.S. reports speaker honoraria from Sanofi, Incyte, and MSD. K.R. Kite/Gilead: Research Funding, Consultancy, Honoraria and travel support; Novartis: Honoraria; BMS/Celgene: Consultancy, Honoraria; Pierre-Fabre: travel support. CSL Behring: Consultancy. AB reports consultancy with BMS and AbbVie.
